Hormone blocker added to chemo for bladder cancer: early study halted
NCT ID NCT05839119
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested adding a testosterone-lowering drug (degarelix) to standard chemotherapy for people with muscle-invasive bladder cancer that has testosterone receptors. Only 2 people enrolled before the study was stopped. The goal was to see if the combination could eliminate all cancer before bladder removal surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGEN RECEPTOR POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02912, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
- New combo aims to wipe out rare bladder cancer before surgery
- Bladder cancer patients may avoid surgery with new drug
- New combo therapy for bladder cancer passes first safety test?
- Experimental combo aims to supercharge cancer immunotherapy
- Step up to surgery: daily walks may cut bladder cancer operation risks